BridgeBio Oncology Therapeutics Inc. (BBOT) vs Standard BioTools Inc. (LAB)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and Standard BioTools Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.59HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
LAB
Standard BioTools Inc.
$0.79HealthcareDelayed quote: Oct 6, 2026, 9:58 AM EDT
Total return — BBOT vs LAB
growth of $100 · dividends reinvested · last 3yBBOT -64.7% (-29.3%/yr)LAB -67.8% (-31.5%/yr)BBOT compounded faster over this window
BBOT LAB
BBOT vs LAB: by the numbers
- •LAB is the larger company ($309M vs $288M market cap).
- •Both run net losses; BBOT's is the smaller (0.00% vs -103.29% net margin).
Metrics side by side
Valuation
| Metric | BBOT | LAB |
|---|---|---|
| P/S ratio | N/A | 3.66 |
| P/B ratio | 0.89 | 0.57 |
Profitability
| Metric | BBOT | LAB |
|---|---|---|
| Gross margin | 0.00% | 49.14% |
| Operating margin | 0.00% | -109.34% |
| Net margin | 0.00% | -103.29% |
| ROE | -56.36% | -16.18% |
| ROIC | -61.10% | -14.06% |
Growth (annualized)
| Metric | BBOT | LAB |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -10.62% |
| Total return CAGR (5Y) | N/A | -32.98% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.